Every fortnight, we recommend one open-ended equity diversified fund that has the best potential of returns for the next one year considering its constituents remain the same.

The Sensex recently crossed the historic 70,000 milestone, and the Nifty surpassed the 21,000 mark for the first time, marking uncharted territory for Indian stock markets. These moments are bittersweet for retail investors, combining pride in India's markets becoming the 4th largest globally with concerns about the market's ascent, leading to the inclination to book profits. In today's dynamic financial landscape, unbiased investing is paramount for optimising portfolios amidst a sea of information, opinions, and potential biases that can sway decision-making. 

The common tendency among those who invest in mutual funds is to simply look at some data and pick out the one that has been at the top, assuming that a fund which is performing well today will continue to do so in the future as well. There is something terribly wrong with such a strategy if you want your mutual fund to create wealth over the long term. The article explains the factors that must be taken into consideration prior to choosing the winner 

Your extensive coverage regarding pharma funds was insightful.

As we close the year 2023, it's evident that the industry is poised for a monumental milestone. The imminent crossing of the ₹50 lakh crore mark in Asset Under Management (AUM) in 2023 signals a remarkable trajectory, notably highlighting the industry's exponential growth.

In the alluring world of mutual fund investment, choosing from the myriad of options can be daunting for investors.

A prudent strategy for conservative to moderate investors involves considering funds that blend equity and debt, offering stability amid equity fluctuations.

Every fortnight, we recommend one open-ended equity diversified fund that has the best potential of returns for the next one year considering its constituents remain the same.

At the core of mutual funds lies the principle of diversification.

Investors often assume that investing in the pharmaceutical sector is a safe bet given that its products and services are always in demand.